Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Qualit-E-SpeakPharma-Insert
    X

    Find drug development pipeline and deal Updates information

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type

              Companies

              OSE Immunotherapeutics SA

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              FRANCE France

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Drug Discovery Chemistry

              Participation Not Confirmed

              Update your events

              OSE Immunotherapeutics and Servier Amend the Global Licensing Option Agreement

              Contact the Supplier

              Lead Product(s): OSE-127

              Therapeutic Area: Immunology

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Servier

              Deal Size: $21.4 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement March 17, 2020

              Details:

              In December 2016, OSE Immunotherapeutics granted Servier a two-step option agreement to acquire the exclusive worldwide license to develop and commercialize OSE-127.

              MaaT Pharma

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              FRANCE France

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Drug Discovery Chemistry

              Participation Not Confirmed

              Update your events

              MaaT Pharma Announces €18 Million Series B Financing

              Contact the Supplier

              Lead Product(s): MaaT013

              Therapeutic Area: Immunology

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: SymBiosis

              Deal Size: $19.5 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing February 05, 2020

              Details:

              The funding will continue the clinical development of the company's current pipeline as well as the extension to other indications in oncology.

              PharmaCompass__DigitalAd